<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586430</url>
  </required_header>
  <id_info>
    <org_study_id>929-05</org_study_id>
    <secondary_id>929-05</secondary_id>
    <nct_id>NCT00586430</nct_id>
  </id_info>
  <brief_title>The Impact of Lorazepam on Cognition in APOE e4 Carriers</brief_title>
  <official_title>The Impact of Lorazepam on Cognition in APOE e4 Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We expect the results of this pilot study to justify a larger study that follows people to
      determine if certain tests of memory and attention, performed while sleepiness is induced by
      a single dose of lorazepam (a widely used anti-anxiety medication) could predict an
      individual's risk of developing AD. We plan to compare cognitively normal people who possess
      a common gene that increases risk for AD— the apolipoprotein E (APOE) e4 allele—to
      individuals without this gene. We hypothesize that a single 2 mg dose of lorazepam will cause
      more cognitive impairment in carriers of the APOE e4 allele than in noncarriers, and that the
      carriers will recover more slowly from these impairments than noncarriers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to compare measures of memory and information processing speed at 2.5 hours and 5
      hours after the administration of a 2 mg dose of lorazepam or placebo in cognitively normal,
      50-65 year old APOE e4 carriers and noncarriers, and determine the differential impact of
      lorazepam on cognition at each time point. Twenty carriers and 20 noncarriers matched for
      age, sex, and education will be drawn from a database of persons who have already undergone
      genotyping for an ongoing study at the Mayo Clinic, excluding people with evidence of
      depression or cognitive impairment and other medical, neurological or psychiatric conditions.
      Using a double blind, crossover design, subjects will receive either placebo or a 2 mg dose
      of lorazepam after baseline testing. Equivalent tests will be repeated 2.5 and 5 hours post
      challenge. The data analysis will compare APOE e4 carriers to noncarriers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Groton Maze Learning Task</measure>
    <time_frame>baseline, 2.5 hours and 5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Auditory Verbal Learning Test</measure>
    <time_frame>baseline, 2.5 hours and 5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-back test</measure>
    <time_frame>baseline, 2.5 hours and 5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single 2 mg dose of lorazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
    <description>single 2 mg dose of lorazepam</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Ativan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose of placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a score of at least 28 on the MMSE

          -  a score of less than 10 points on the HAM-D-17

          -  age 50-65

          -  genotype APOE e3/e4 or APOE e4 non-carriers

          -  cognitively normal

        Exclusion Criteria:

          -  significant medical, psychiatric, or neurological illnesses

          -  use of benzodiazepines within the previous four weeks

          -  currently using sedating antihistamines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia M Stonnington, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <last_update_submitted>December 21, 2007</last_update_submitted>
  <last_update_submitted_qc>December 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cynthia Stonnington, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>apolipoprotein E e4</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>somnolence</keyword>
  <keyword>Early detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

